Core Advantage: Triple-layered protection ensures absolute security
1. A groundbreaking breakthrough in inactivation efficacy

Precise coordinated high-temperature, high-pressure operation: Featuring a double-layer FBE anti-corrosion jacket and multi-section flow-directing coils, saturated steam penetration efficiency is improved by 40%, and the temperature distribution within the chamber at 121°C achieves uniformity of ±0.5°C, ensuring a ≥6-log kill rate for recalcitrant pathogens such as Bacillus stearothermophilus.
Chemical–physical dual-mode inactivation: Optionally equipped with a hydrogen peroxide (VHP) atomization and spraying system or an acid–alkali agent injection unit, enabling deep degradation of specific contaminants such as prions and heat-resistant endotoxins, with residual DNA/RNA fragments ≤10 pg/mL.
2. Biological Seal Protection System

Negative-pressure double-seal mechanism: The vessel is manufactured using laser welding for seamless integration (weld porosity < 0.01%), combined with a magnetic-drive agitator sealing system to eliminate the risk of mechanical shaft seal leakage; the chamber maintains a constant negative pressure of **-30 Pa**, and, in conjunction with a HEPA exhaust filtration unit, ensures zero aerosol release.
Intelligent Pressure-Protection System: Equipped with a pressure-sensing diaphragm rupture monitoring module, it automatically shuts off the feed line and activates emergency cooling when abnormal pressure builds up in the inner vessel, thereby preventing tank rupture.
3. End-to-end digital traceability

Equipped with an industrial IoT control terminal, it records key parameters such as temperature–pressure–time (T/P/t) curves and inactivant concentration in real time, generating electronic signature reports compliant with 21 CFR Part 11.
Supports 3D dynamic heat map analysis, automatically identifies cold spot areas and recommends re-inactivation protocols, and stores audit-trail data for ≥10 years.
Deep Applications Across Multiple Industries: From the Lab to Industrialization
Biopharmaceuticals: Safeguarding the Safety Chain of Vaccines and Blood Products
A national-level vaccine company uses the Haoran fully automated cell culture inactivation platform to inactivate rabies virus in Vero cell substrates, reducing the viral titer to ≤0.1 LD₅₀/mL and achieving WHO pre-qualification.
Blood products facilities have implemented a low-temperature plasma inactivation system (operating at 37°C) that achieves an HBV/HCV viral inactivation efficiency of ≥99.9999% while preserving the activity of clotting factors.
Hazardous Chemicals: Achieving Harmless Transformation of High-Risk Waste
Leading agrochemical companies are equipping their facilities with inactivation tank systems for organophosphorus-containing wastewater, employing an alkaline hydrolysis process (pH > 12, 80°C) to degrade the highly toxic methyl parathion into biodegradable small molecules, achieving a toxicity reduction rate of 99.8%.
A semiconductor factory uses a closed-loop inactivation system for cyanide-containing waste liquid to convert cyanide (CN⁻) into non-toxic N₂ and CO₂ under hypochlorite catalysis, with a processing capacity of 5 tons per day.
Microbial Research: Strengthening the Laboratory Biosafety Barrier
The BSL-3 laboratory is equipped with a double-door pass-through autoclave for inactivating Mycobacterium tuberculosis–contaminated cultures, employing an enhanced sterilization protocol of 135°C for 45 minutes. Exhaust gases undergo two-stage incineration and are discharged in compliance with ISO Class 5 cleanliness standards.
Gene-editing companies use CRISPR vector inactivation workstations that employ a combined UV–ozone treatment to completely degrade plasmid DNA, thereby preventing the release of genetically engineered microorganisms.
Food Industry: Solving the Dilemma of Allergens and Toxins
Dairy companies use β-lactoglobulin-directed inactivation tanks and a specific enzymatic hydrolysis process to disrupt allergenic protein epitopes while preserving 80% of lactoferrin activity, thereby meeting the needs of consumers with allergies.
Grain and oil processing plants have implemented an aflatoxin degradation system that uses ozone micro- and nano-bubble technology to convert B1 toxin into the non-toxic B2a, with residual levels below 1 ppb.